On April 20, 2017 Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, reported that data from a prospective biomarker analysis of a Phase 3 study using Progenics’ automated bone scan index (aBSI) will be presented in an oral session at the upcoming 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which will be held from June 2-6, 2017 in Chicago, Illinois (Press release, Progenics Pharmaceuticals, APR 20, 2017, View Source [SID1234518650]). In addition, a second abstract from a study on translating the Prostate Cancer Working Group (PCWG) criteria into a biomarker for prostate cancer will be presented in a poster session. Schedule your 30 min Free 1stOncology Demo! The schedule for the presentations at ASCO (Free ASCO Whitepaper) is as follows:
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Date & Time: Saturday, June 3, 2017, 1:15 PM-4:15 PM
Session Title: Genitourinary (Prostate) Cancer
Session Type: Oral Abstract Presentation
Title: Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC)
Abstract No.: 5006
Date & Time: Monday, June 5, 2017, 1:15 PM-4:15 PM
Session Title: Genitourinary (Prostate) Cancer
Session Type: Poster Session
Title: Translating Prostate Cancer Working Group (PCWG) criteria into a quantitative progression biomarker in metastatic Castration Resistant Prostate Cancer (mCRPC)
Abstract No.: 5068